The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a lawsuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback